Related Experiment Video
Updated: Jun 10, 2026
05:36
Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron
Published on: February 23, 2024
Deferiprone.
Antonio Piga1, Simona Roggero, Ilaria Salussolia
1Thalassemia Center, University of Turin, Orbassano, Italy. antonio.piga@unito.it
Annals of the New York Academy of Sciences
|August 18, 2010
Summary
Deferiprone (DFP) is effective for managing iron overload, particularly in thalassemia, but requires careful monitoring due to potential side effects like neutropenia. Further trials are needed to compare its long-term value against other iron chelators.
Area of Science:
- Pharmacology and Therapeutics
- Hematology
- Toxicology
Background:
- Deferiprone (DFP) is an oral iron chelator used in various conditions, with extensive data from transfusion-dependent thalassemia.
- Iron overload management is critical for patients with chronic transfusion needs.
Purpose of the Study:
- To review the safety, tolerability, and efficacy of Deferiprone (DFP) in managing iron overload.
- To highlight the role of DFP in preventing iron toxicity, especially cardiac iron loading.
Main Methods:
- Systematic review of existing literature on Deferiprone (DFP) use.
- Analysis of safety profiles, including adverse events like neutropenia and agranulocytosis.
- Evaluation of efficacy data regarding iron reduction, particularly in cardiac iron.
Main Results:
- DFP exhibits a known safety profile with potential gastrointestinal issues, liver enzyme elevation, and hematological concerns (neutropenia, agranulocytosis).
- Its efficacy is comparable to other iron chelators, with dosage optimization being key for liver iron reduction.
- DFP demonstrates effectiveness in reducing cardiac iron, both as monotherapy and in combination with deferoxamine.
Conclusions:
- Deferiprone (DFP) plays a significant role in managing iron overload, especially in preventing cardiac complications.
- Close monitoring of blood counts is essential due to the risk of severe neutropenia and agranulocytosis.
- Well-designed randomized controlled trials are necessary to directly compare the long-term benefits of DFP against other iron chelators.
Related Concept Videos
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:16Hepatic Drug Excretion: Influencing Factors
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
01:17Hepatic Drug Excretion: Enterohepatic Cycling
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
01:15Drug Dosage Regimen: Overview
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...